10 completed, 5 unknown, 3 terminated. 18 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 10, Unknown 5, Terminated 3 |
| Phase 1 | 3 | Unknown 2, Completed 1 |
Follow Baraclude: new trials by email Literature Review of Baraclude trials Research Report on Baraclude
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB ZM-H1505R, ZM-H1505R placebo, Baraclude - Hepatitis B, Chronic | Phase 2 | Unknown | Shanghai Zhimeng Biopharma, Inc. | 90 | 2022-11-11 | 2023-05-08 |
| A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B APG-1387, Entecavir 0.5 mg - Hepatitis B, Chronic Hep B | Phase 2 | Unknown | Ascentage Pharma Group Inc. | 122 | 2020-06-03 | 2021-08-26 |
| Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) ARC-520, entecavir, pegylated interferon alpha 2a - Hepatitis B, Hepatitis D | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 79 | 2015-12-01 | 2026-01-13 |
| A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB HPDC-T cells & Entecavir, Entecavir, HPDC-T cells & IFN-a-2a - Chronic Hepatitis B | Phase 1 / Phase 2 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 450 | 2015-11-01 | 2015-11-26 |
| Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus ARC-520, Placebo, Entecavir - Chronic Hepatitis B | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 4 | 2015-08-01 | 2025-11-03 |
| A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection ARC-520, Placebo, entecavir - Hepatitis B, Chronic | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 58 | 2014-03-01 | 2026-01-13 |
| Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL Entecavir, Lamivudine - Non-Hodgkin Lymphoma, Hepatitis B Reactivation | Phase 2 | Unknown | Fudan University | 82 | 2013-02-01 | 2013-08-02 |
| Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB) Pegalyted interferon, Entecavir - Chronic Hepatitis B | Phase 1 / Phase 2 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 20 | 2012-03-01 | 2012-05-02 |
| Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen pegIFN, pegIFNα-2a, PegIFN lambda - Hepatitis B Virus | Phase 2 | Completed | Bristol-Myers Squibb | 197 | 2010-11-01 | 2015-10-09 |
| Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients Therapeutic HBV vaccine, entecavir, placebo - Chronic Hepatitis B | Phase 2 | Completed | Chongqing Jiachen Biotechnology Ltd. | 378 | 2010-06-01 | 2019-06-26 |
| Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B LB80380 90 mg, LB80380 150 mg, entecavir 0.5 mg - Chronic Hepatitis B | Phase 2 | Completed | LG Life Sciences | 115 | 2009-08-01 | 2012-10-05 |
| A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection Entecavir - Hepatitis B, Chronic | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 64 | 2007-06-30 | 2018-05-02 |
| Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease. Tenofovir disoproxil fumarate (tenofovir DF; TDF), Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), Entecavir (ETV) - Chronic Hepatitis B | Phase 2 | Completed | Gilead Sciences | 112 | 2006-04-01 | 2013-04-25 |
| An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection Entecavir - Chronic Hepatitis B | Phase 2 | Completed | Bristol-Myers Squibb | 282 | 2003-12-01 | 2011-01-31 |
| A Phase II Dose Response Study in Japan in Chronic Hepatitis B Entecavir - Chronic Hepatitis B | Phase 2 | Completed | Bristol-Myers Squibb | 120 | 2003-08-01 | 2010-02-02 |
| A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection Entecavir - Chronic Hepatitis B | Phase 2 | Completed | Bristol-Myers Squibb | 60 | 2003-02-01 | 2010-08-06 |
| Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy Entecavir - Chronic Hepatitis B | Phase 2 | Completed | Bristol-Myers Squibb | 84 | 2002-12-01 | 2011-01-31 |
| Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials Entecavir, Lamivudine - Hepatitis B Virus, HBV | Phase 2 | Completed | Bristol-Myers Squibb | 1053 | 2001-01-01 | 2012-08-23 |
Hepatitis B, Chronic (14) · Hepatitis B (6) · Hepatitis (2) · Hepatitis D (1) · Lymphoma, Non-Hodgkin (1)
Bristol-Myers Squibb (7) · Arrowhead Pharmaceuticals (3) · Ascentage Pharma Group Inc. (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Chongqing Jiachen Biotechnology Ltd. (1) · Fudan University (1) · Gilead Sciences (1) · LG Life Sciences (1) · Shanghai Zhimeng Biopharma, Inc. (1) · Third Affiliated Hospital, Sun Yat-Sen University (1)
China (6) · South Korea (4) · Taiwan (4) · United States (4) · Canada (3) · Australia (2) · France (2) · Germany (2) · Hong Kong (2) · Italy (2) · Japan (2) · Singapore (2) · Argentina (1) · Bangladesh (1) · Belgium (1)
Bruce Given, MD (1) · John Flaherty, PharmD (1) · Junqi Niu (1) · LanJuan Li, Ph.D. (1) · Lubiao Chen, MD.&PHD. (1) · Mamun A Mahtab, MSc MD FACG (1) · Ye Guo, MD (1) · Yifan Zhai, MD, PhD (1)
PMID 21254162, PMID 22233350, PMID 26739688, PMID 28611778, PMID 33712437
2015 (1)